Evidence map›Paper›PMID 39476147›Full record

ArticleJournal of neuro-oncology2025

Molecular characterization of gliosarcoma reveals prognostic biomarkers and clinical parallels with glioblastoma.

Lucy Chen, Emanuelle Rizk, Mohamed Sherief, Michael Chang, Calixto-Hope Lucas, Chetan Bettegowda, Victoria Croog, Debraj Mukherjee, Jordina Rincon-Torroella, David Olayinka Kamson and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lucy Chen *Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Emanuelle Rizk *Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Mohamed SheriefSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Michael ChangSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Calixto-Hope LucasDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Chetan BettegowdaDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Victoria CroogDepartment of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Debraj MukherjeeDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jordina Rincon-TorroellaDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David Olayinka KamsonSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Peng HuangSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Matthias Holdhoff *Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Karisa Schreck *Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. ksolt1@jhmi.edu.ORCID https://orcid.org/0000-0001-7181-3269

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Cancer Center Core Grant of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCI P30 CA006973Department of Defense W81XWH-21-1-0251NCI NIH HHS P30 CA006973
6 · The paper itself

Abstract

purposeGliosarcoma is a rare histopathological variant of glioblastoma, but it is unclear whether distinct clinical or molecular features distinguish it from other glioblastomas. The purpose of this study was to characterize common genomic alterations of gliosarcoma, compare them to that of glioblastoma, and correlate them with prognosis.

methodsThis was a single-institution, retrospective cohort study of patients seen between 11/1/2017 to 1/28/2024. Clinical and genomic data were obtained from the medical record. Results were validated using data from AACR Project GENIE (v15.1-public).

resultsWe identified 87 gliosarcoma patients in the institutional cohort. Compared to a contemporary cohort of 492 glioblastoma, there was no difference in overall survival, though progression free survival was inferior for patients with gliosarcoma (p = 0.01). Several of the most-commonly altered genes in gliosarcoma were more frequently altered than in glioblastoma (NF1, PTEN, TP53), while others were less frequently altered than in glioblastoma (EGFR). CDKN2A/CDKN2B/MTAP alterations were associated with inferior survival on univariate Cox (HR = 5.4, p = 0.023). When pooled with 93 patients from the GENIE cohort, CDKN2A/B (HR = 1.75, p = 0.039), RB1 (HR = 0.51, p = 0.016), LRP1B (p = 0.050, HR = 2.0), and TSC2 (HR = 0.31, p = 0.048) alterations or loss were significantly associated with survival. These effects remained when controlled for age, sex, and cohort of origin with multivariate Cox.

conclusionGliosarcoma has a similar overall survival but worse response to treatment and different mutational profile than glioblastoma. CDKN2A/B loss and LRP1B alterations were associated with inferior prognosis, while RB1 or TSC2 alterations were associated with improved outcomes. These findings may have implications for clinical management and therapeutic selection in this patient population.

Indexed as

Biomarkers, TumorBrain NeoplasmsGlioblastomaGliosarcomaAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateYoung AdultBiomarkers, TumorCDKN2A/BLRP1BMolecular profilingPrognostic markerProject GENIETSC2

Identifiers

PMID39476147
PMCPMC11695672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.